Table of Contents Table of Contents
Previous Page  40 / 66 Next Page
Information
Show Menu
Previous Page 40 / 66 Next Page
Page Background

116

en qué grupo específico de pacientes con FPI. Las

recomendaciones de las guías clínicas interna-

cionales se basan en la escasa evidencia clínica

y experimental disponible con las limitaciones

inherentes que conlleva el estudio de este proble-

ma. En algunos contextos, estos procesos podrían

dar lugar a recomendaciones controvertidas que

tienen efectos importantes en la atención clínica.

En virtud de los resultados de la evidencia clínica

publicada hasta la fecha, estudios de calidad mo-

derada y baja, se sugiere que en algunos pacientes

con Fibrosis Pulmonar Idiopática la aspiración

podría determinar la progresión o gatillar exacer-

baciones de la enfermedad, pero que la mayoría

de las EA-FPI no estarían relacionadas con este

fenómeno.

Bibliografía

1.-

Raghu G,

Rochwerg B,

ZhangY

, GarcíaCA,

AzumaA,

Behr J, et al.

American Thoracic Society;

European Respiratory society; Japanese Respiratory

Society

;

Latin American Thoracic Association. An Offi-

cial ATS/ERS/JRS/ALAT Clinical Practice Guideline:

Treatment of Idiopathic Pulmonary Fibrosis. An Update

of the 2011 Clinical Practice Guideline. Am J Respir

Crit Care Med 2015; 192: e3-19.

2.- King TE, Pardo A, Selman M. Idiopathic pulmo-

nary fibrosis. Lancet 2011; 378: 1949-61.

3.- Ware LB, Matthay MA. The acute respiratory

distress syndrome. N Engl J Med 2000; 342: 1334-49.

4.- Lee JS, Collard HR, Raghu G, Sweet MP,

Hays SR, Campos GM, et al. Does chronic microas-

piration cause idiopathic pulmonary fibrosis? Am J Med

2010; 123: 304-11.

5.- Collard HR, Moore BB, Flaherty KR,

Brown KK, Kaner RJ, King TE Jr,

et al. Acute

exacerbations of idiopathic pulmonary fibrosis. Am J

Respir Crit Care Med 2007; 176: 636-43.

6.-

Shamseer L, Moher D, Clarke M, Ghersi D,

Liberati A,

Petticrew M,

Shekelle P

,

Stewart LA; PRISMA-P Group.

Preferred reporting

items for systematic review and meta-analysis protocols

(PRISMA-P) 2015: elaboration and explanation.

BMJ

2015; 350: g7647.

7.- Raghu G, Freudenberger TD, Yang S, Cur-

tis JR, Spada C, Hayes J, et al. High prevalence of

abnormal acid gastro-oesophageal reflux in idiopathic

pulmonary fibrosis. Eur Respir J 2006; 27: 136-42.

8.- Tobin RW, Pope CE 2

nd

, Pellegrini CA,

Emond MJ, Sillery J, Raghu G.

Increased prevalence of

gastroesophageal reflux in patients with idiopathic pul-

monary fibrosis. Am J Respir Crit Care Med 1998; 158:

1804-8.

9.- Sweet MP, Patti M G, Leard LE,

Golden JA, Hays SR, Hoopes C,

et al. Gastroesophageal reflux

in patients with idiopathic pulmonary fibrosis referred

for lung transplantation. J Thorac Cardiovasc Surg

2007; 133: 1078-84.

10.- Bandeira CD, Rubin AS, Cardoso PF,

Mo- reira JdaS, Machado Mda M.

Prevalence of

gastroesophageal reflux disease in patients with idio-

pathic pulmonary fibrosis. J Bras Pneumol 2009; 35:

1182-9.

11.- Demeter P, PapA. The relationship between gastroe-

sophageal reflux disease and obstructive sleep apnea. J

Gastroenterol 2004; 39: 815-20.

12.- Raghu G, Yang ST, Spada C, Hayes J, Pelle-

grini CA. Sole treatment of acid gastroesophageal

reflux in idiopathic pulmonary fibrosis: a case series.

Chest 2006; 129: 794-800.

13.- Fahim A, Crooks M, Hart SP. Gastroesophageal

reflux and idiopathic pulmonary fibrosis: a review. Pulm

Med 2011; 2011: 634613. doi: 10.1155/2011/634613.

14.- Patti MG, Debas HT, Pellegrini CA. Clinical

and functional characterization of high gastroesophageal

reflux. Am J Surg 1993; 165: 163-6.

15.- D’Ovidio F, Singer LG, Hadjiliadis D,

Pierre A, Waddell TK, de Perrot M,

et al. Prevalence

of gastroesophageal reflux in end-stage lung disease

candidates for lung transplant. Ann Thorac Surg 2005;

80: 1254-60.

16.- Hoppo T, Sanz AF, Nason KS,

Carroll T L,

Rosen C,

Normolle DP

, et al. How much

pharyngeal exposure is “normal”? Normative data for

laryngopharyngeal reflux events using hypopharyngeal

multichannel intraluminal impedance (HMII). J Gas-

trointest Surg 2012; 16: 16-24.

17.- Koufman JA. The otolaryngologic manifestations

of gastroesophageal reflux disease (GERD): A clinical

investigation of 225 patients using ambulatory 24-hour

pH monitoring and an experimental investigation of the

role of acid and pepsin in the development of laryngeal

injury. Laryngoscope 1991; 101 (4 Pt 2 Suppl 53): 1-78.

18.- Hershcovici T, Jha LK, Johnson T, Gerson

L, Stave C, Malo J, et al.

Systematic review: the relationship between interstitial lung diseases and gastro-oesophageal reflux disease.

Aliment Pharmacol

Ther 2011; 34: 1295-305.

19.- Lee JS, Song JW, Wolters PJ, Elicker BM,

King TE Jr, Kim DS, et al. Bronchoalveolar lavage

pepsin in acute exacerbation of idiopathic pulmonary

fibrosis. Eur Respir J 2012; 39: 352-8.

20.- Tcherakian C, Cottin V, Brillet PY, Frey-

net O, Naggara N, Carton Z, et al. Progression

of idiopathic pulmonary fibrosis: lessons from asymme-

trical disease. Thorax 2011; 66: 226-31.

21.- Lee JS, Collard HR, Anstrom KJ, Martínez

FJ, Noth I, Roberts RS, et al. Anti-acid treatment

and disease progression in idiopathic pulmonary fibro-

sis: an analysis of data from three randomised controlled

trials. Lancet Respir Med 2013; 1: 369-76.

F. Tirapegui S. et al.

Rev Chil Enferm Respir 2017; 33: 111-117